Payment overview · 2025
General Payments
$14,483.33
113 reported records · 24 companies
Healthcare provider profile · identity verified
Michael William Lenihan, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · GLENS FALLS, NY · NPI 1285727792
Verified facts
What the public records show
CMS Open Payments records show Michael William Lenihan, M.D. received $14,483.33 in general payments during 2025 across 113 reported records.
ARGENX US, INC. accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Nurtec Odt, Qulipta, Rexulti, Ubrelvy, Valtoco.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ubrelvy by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Rexulti by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Valtoco by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $5,891.97 | 40.7% | 13 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $4,487.04 | 31.0% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $2,225.30 | 15.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $287.14 | 2.0% | 19 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $234.22 | 1.6% | 7 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $171.81 | 1.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $169.48 | 1.2% | 19 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $148.99 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.59 | 1.0% | 7 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$102.08 | 0.7% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$80.46 | 0.6% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $78.01 | 0.5% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $66.09 | 0.5% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $62.38 | 0.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.33 | 0.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.19 | 0.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.88 | 0.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $40.07 | 0.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.31 | 0.2% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $26.12 | 0.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $25.12 | 0.2% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.04 | 0.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.39 | 0.1% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $21.32 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,425.00 | 4 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,430.00 | 4 |
| Food and Beverage | $2,446.01 | 100 |
| Travel and Lodging | $1,182.32 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $5,891.97 | 13 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $4,487.04 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $287.14 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $257.75 | 15 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $210.48 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $171.81 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $148.25 | 18 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $139.59 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $120.54 | 16 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $80.46 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $66.09 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $62.38 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $59.29 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $58.33 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $50.43 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $48.19 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $47.88 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 53 | exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
39 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 570 | 86 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 337 | 69 |
| Topiramate | Topiramate | 306 | 43 |
| Donepezil Hcl | Donepezil Hcl | 288 | 71 |
| Lacosamide | Lacosamide | 271 | 37 |
| Primidone | Primidone | 252 | 47 |
| Gabapentin | Gabapentin | 246 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 227 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 204 | 36 |
| Oxcarbazepine | Oxcarbazepine | 124 | 20 |
| Lamotrigine | Lamotrigine | 118 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 116 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 22 |
| Phenobarbital | Phenobarbital | 104 | 12 |
| Pregabalin | Pregabalin | 97 | 17 |
| Memantine Hcl | Memantine Hcl | 93 | 20 |
| Carbamazepine Er | Carbamazepine | 81 | 13 |
| Vimpat | Lacosamide | 73 | suppressed |
| Teriflunomide | Teriflunomide | 70 | suppressed |
| Baclofen | Baclofen | 69 | 15 |
| Divalproex Sodium | Divalproex Sodium | 68 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 67 | suppressed |
| Lamotrigine Er | Lamotrigine | 64 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 13 |
| Prednisone | Prednisone | 55 | 12 |
| Xcopri | Cenobamate | 54 | suppressed |
| Ubrelvy | Ubrogepant | 53 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Rivastigmine | Rivastigmine | 45 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 44 | 12 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 44 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 43 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 42 | suppressed |
| Rexulti | Brexpiprazole | 42 | suppressed |
| Zonisamide | Zonisamide | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Botox | Onabotulinumtoxina | 39 | 19 |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 38 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 37 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 34 | suppressed |
| Lamictal | Lamotrigine | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Ingrezza | Valbenazine Tosylate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | 13 |
| Topamax | Topiramate | 27 | suppressed |
| Azathioprine | Azathioprine | 26 | suppressed |
| Entacapone | Entacapone | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 24 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Depakote | Divalproex Sodium | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Levetiracetam Er | Levetiracetam | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Carbatrol | Carbamazepine | 16 | suppressed |
| Dalfampridine Er | Dalfampridine | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Valtoco | Diazepam | 15 | suppressed |
| Armodafinil | Armodafinil | 14 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Mestinon | Pyridostigmine Bromide | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Tegretol | Carbamazepine | 13 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Lamotrigine Odt | Lamotrigine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,483.33 · 113 records | ARGENX US, INC. | BRIUMVI, DUROLANE, Dysport, INGREZZA, KISUNLA, Leqembi, Mavenclad, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, PANZYGA, QULIPTA, REXULTI, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYVGART HYTRULO, WAINUA, WAKIX, ZAVZPRET, ZTLido, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error